Genetic testing plays a pivotal role in the management of maturity onset diabetes of the young (MODY), driving the choice of the treatment, the assessment of the risk for complications, and the need for genetic counseling. |
Patients with glucokinase (GCK)-MODY should not be treated, except during pregnancy and when the fetus is healthy. |
Sulphonylureas are effective in managing patients with HNF1A- and HNF4A–MODY, while additional treatment with other oral hypoglycemic agents may improve blood glucose control. |
Avoid treating carriers of HNF1A and HNF4A mutations with sulphonylureas during pregnancy. |
Introduction
MODY type Gene (gene location) | Protein function | Age at onset | Phenotype | Treatment |
---|---|---|---|---|
MODY1 HNF4A (20q13.12) | Transcription factor | < 18 years | Progressive decrease in insulin secretion; worsening of glucose control; high risk of microvascular complications; low levels of apolipoproteins and triglycerides; neonatal macrosomia; neonatal hypoglycemic events | Diet, sulphonylureas, insulin |
MODY2 GCK (7p13) | Enzyme | Pre-adolescence | Mild hyperglycemia Excellent prognosis | Treatment is unnecessary (usually) |
MODY3 HNF1A (12q24.31) | Transcription factor | < 25 years | Decreased insulin secretion; high risk of microvascular complications; low glucose renal threshold | Sulphonylureas (additional meglitinides, GLP-1 RA, SGLT-2 inhibitors), insulin |
MODY4 PDX1 (13q12.2) | Transcription factor | Postpuberty | Mild form of diabetes | OHAs, insulin |
MODY5 HNF1B (17q12) | Transcription factor | < 25 years | Decreased insulin secretion with progressive worsening of glucose control; genitourinary malformations (renal cysts, azoospermia, uterus anomaly, etc) | OHAs (sulfonylurea or repaglinide), insulin |
MODY6 NEUROD1 (2q31.3) | Transcription factor | Variable | Different degrees of hyperglycemia | OHAs, insulin |
MODY7 KLF11 (2p25.1) | Transcription factor | Variable | Decreased sensitivity to insulin; mild hyperglycemia | Insulin |
MODY8 CEL (9q34.13) | Lipolytic enzyme | > 25 years | Impaired endocrine and exocrine pancreatic function | OHAs, insulin |
MODY9 PAX4 (7q32.1) | Transcription factor | Postpuberty | Progressive hyperglycemia; occurrences of ketoacidosis | Diet, OHAs, insulin |
MODY10 INS (11p15.5) | Hormone | > 10 years | Hyperglycemia; diabetes | Diet, insulin |
MODY11 BLK (8p23.1) | Enzyme | Variable | Hyperglycemia; diabetes | Diet, OHAs, insulin |
MODY12 ABCC8 (11p15.1) | Subunit of ATP-sensitive channels | Variable | Diabetes | Sulphonylureas |
MODY13 KCNJ11 (11p15.1) | Subunit of ATP-sensitive channels | After second decade of life | Diabetes | Sulphonylureas |
MODY14 APPL1 (3p14.3) | Adaptor protein | 10–50 years | Hyperglycemia; diabetes | Diet, OHAs, insulin |
MODY type | Tissue distribution | Extra-pancreatic features |
---|---|---|
MODY1 | Liver, kidney, intestine, pancreatic islets and insulinoma cells | Macrosomia with hyperinsulinemic hypoglycemia; low levels apolipoproteins and triglycerides; atypical Fanconi syndrome with hypercalciuria and nephrocalcinosis in carriers of the p.Arg76Trp (R76W) mutation |
MODY2 | Liver and pancreatic beta-cells | Not described |
MODY3 | Liver, pancreatic islets, kidney | Renal glycosuria |
MODY4 | Pancreatic beta-cells | Overweight/obesity in some patients |
MODY5 | Kidney, liver, bile ducts, thymus, genital tract, pancreas, lung, and gut | Renal cysts; progressive renal dysfunction, leading to chronic renal insufficiency and failure; internal genital abnormalities (in female carriers); pancreatic hypoplasia, pancreatic cysts |
MODY6 | Neurons in the central and peripheral nervous systems, pancreatic endocrine cells, intestine | Overweight/obesity in some patients; intellectual disabilities with brain abnormalities (uncommon) |
MODY7 | Ubiquitously expressed | Not described |
MODY8 | Lactating mammary gland and pancreas | Pancreatic atrophy with exocrine pancreatic insufficiency; fibrosis and lipomatosis causing hyperglycemia |
MODY9 | Germ layers in the mammalian embryo | Not described |
MODY10 | Pancreas, eye, limb | Not described |
MODY11 | Lymphoblastoid cell lines, spleen, pancreatic islets, liver, leukocytes, ovary, muscle, testis | Overweight/obesity in some patients |
MODY12 | Pancreatic beta-cells | Not described |
MODY13 | Pancreatic beta-cells, neurons, muscle cells | Not described |
MODY14 | Highly expressed in skeletal muscle, heart, ovary, and pancreas | Overweight/obesity in some patients |
Methods
HNF4A–MODY (MIM# 125850) or MODY1
Genetic Defect and Pathophysiological Effects
Clinical Presentation
Extra-Pancreatic Associations
Management Plan
When to Suspect
Pregnancy
MODY type | Before pregnancy | First trimester | Second trimester | Third trimester | Management |
---|---|---|---|---|---|
HNF4A–MODY | Option 1 (to be preferred): switch from sulphonylurea to insulin | Continue insulin | 1. Fetal growth assessment with ultrasound at 2-week intervals after 28 weeks 2. Elective caesarean section or induction of labor between 35 and 38 weeks 3. Switch to previous sulphonylurea once breastfeeding is completed 4. Monitor neonatal glycemia | ||
Option 2: continue sulphonylurea medication and switch to insulin during pregnancy | Continue sulphonylurea | Switch from sulphonylurea to insulin | Continue insulin | ||
GCK–MODY | Usually no treatment | Mother and fetus carry a GCK mutation: no treatment is needed | No additional management is required | ||
Mother carries a GCK mutation: large dose (>1 IU/kg/day) of insulin is recommended | 1. Induction at 38 weeks 2. Monitor neonatal glycemia | ||||
HNF1A–MODY | Option 1 (to be preferred): switch from sulphonylurea to insulin | Continue insulin | 1. Fetal growth assessment with ultrasound at 2-week intervals after 28 weeks 2. Elective caesarean section or induction of labor between 37 and 39 weeks 3. Switch to previous sulphonylurea once breastfeeding is completed | ||
Option 2: continue on sulphonylurea and switch to insulin during pregnancy | Continue sulphonylurea | Switch from sulphonylurea to insulin | Continue insulin |